Results 31 to 40 of about 1,054 (155)

Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings

The Journal of Headache and Pain, 2022
Background In the absence of head-to-head trials, comprehensive evidence comparing onset of efficacy of novel agents for acute treatment of migraine is lacking.
Pepa Polavieja, Mark Belger, Shiva Kumar Venkata, Stefan Wilhelm, Erin Johansson   +4 more
doaj   +1 more source

Unintended Pregnancies and Breastfeeding Studies during Central Nervous System Drug Development: How Are they Handled, Is There Room for Improvement?

Clinical Pharmacology &Therapeutics, EarlyView.
Pregnant and breastfeeding individuals are routinely excluded from clinical drug development, creating persistent evidence gaps in pharmacology, safety, and dosing. Despite mandatory contraception and pregnancy testing, unintended pregnancies occur, particularly during the development of central nervous system (CNS) medicines used by women of ...
Sam Schoenmakers, Charlotte Bakker, Alexandra Ganev, Florence Butlen‐Ducuing, Corinne S. de Vries   +4 more
wiley   +1 more source

Efficacy of 5-HT1F agonist versus CGRP-antagonists for treatment of acute migraine: A systematic review and network meta-analysis

National Journal of Physiology, Pharmacy and Pharmacology, 2023
Background: Two new classes of drugs approved by USFDA for the treatment of acute migraine are non-peptide Calcitonin Gene-Related Peptide (CGRP) receptor antagonists (rimegepant and ubrogepant) and 5-HT1F receptor agonist lasmiditan.
Sharanabasayyaswamy Basayya Hiremath, Srinivas Devendrappa Lokikere   +1 more
doaj   +1 more source

Real‐world outcomes of zavegepant use in a tertiary care setting using the Migraine Treatment Optimization Questionnaire‐5

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background The introduction of calcitonin gene‐related peptide antagonists has transformed migraine care. Zavegepant, a third‐generation intranasal gepant, offers a nonoral treatment option for acute migraine. Although clinical trials support its efficacy and safety, real‐world data are limited.
Eric Dunn, Bradley Ong, Harpreet Kaur, Roman Popov, Claire Sonneborn, Aarushi Suneja   +5 more
wiley   +1 more source

Longitudinal effects of CGRP‐targeting migraine therapies on blood pressure and body mass index: A 12‐month retrospective analysis

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To compare blood pressure (BP) and body mass index (BMI) trajectories associated with individual calcitonin gene‐related peptide (CGRP)‐targeting migraine therapies versus matched CGRP‐unexposed controls. Background CGRP is a potent vasodilator with established roles in vascular homeostasis and metabolic regulation.
Phillip Phan, Scott Keith, Michael Li, Richard Hass, Wan‐Jen Hsieh, Michael Marmura, Hsiangkuo Yuan   +6 more
wiley   +1 more source

Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial

The Journal of Headache and Pain
Background Rimegepant orally disintegrating tablet (ODT), an oral small-molecule calcitonin gene-related peptide receptor antagonist, is indicated for acute and preventive treatment of migraine in the United States and other countries.
Shengyuan Yu, Aihong Guo, Zhen Wang, Jianguang Liu, Ge Tan, Qian Yang, Mingjie Zhang, Hasiyeti Yibulaiyin, Huisheng Chen, Yongbo Zhang, Robert Croop, Yanhui Sun, Yu Liu, Qian Zhao, Zhihong Lu   +14 more
doaj   +1 more source

Cost-effectiveness analysis of rimegepant for on-demand acute treatment of migraine in China

Frontiers in Neurology
PurposeThis study assesses the cost-effectiveness of rimegepant for the on-demand acute treatment of migraine in the Chinese population, focusing on headache relief within a 2 h timeframe.
Shuo Tian, Yuping Yang, Shenglan Tan, Jiani Luo, Chuanyu Yang, Qiao Liu, Yujin Guo   +6 more
doaj   +1 more source

Real‐world diagnosis and treatment of individuals with migraine in the United States: The Migraine Insights in Diagnosis and Treatment (MIND) study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective The objective of this study was to describe the real‐world diagnosis and treatment patterns of individuals newly diagnosed with migraine in the United States (US). Background Over 10% of adults in the US are living with migraine.
Fred Cohen, Vincent Martin, Avani Patel, Shelby L. Corman, Katie B. Tellor, Meghan Fajardo, D. Cortney Hayflinger, Simon Dagenais   +7 more
wiley   +1 more source

Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine

CNS Drugs, 2023
Rimegepant [Nurtec® ODT (USA); Vydura® (EU)] is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine with or without aura in adults, and for the preventive treatment of episodic migraine in adults.
openaire   +2 more sources

No clinically relevant electrocardiogram effects in a randomized TQT study of single therapeutic/supratherapeutic rimegepant doses in healthy adults

Clinical and Translational Science
A single‐center, phase I, partially double‐blind (double‐blind regarding doses of rimegepant and placebo, and open label with respect to moxifloxacin), randomized, 12‐sequence, four‐period crossover study of therapeutic (75 mg) and supratherapeutic (300 ...
Rajinder Bhardwaj, Michael S. Hanna, Beth A. Morris, Kyle T. Matschke, Richard Bertz, Robert S. Croop, Jing Liu   +6 more
doaj   +1 more source